These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8596297)

  • 21. Changes in prescription patterns of oral contraceptives in a northern Italian province: relation with venous thromboembolism.
    Girolami A; Spiezia L; Vianello F; Girolami B; Fabris F
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):125-30. PubMed ID: 12812381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [What does the micropill bring?].
    Mall-Haefeli M
    Ther Umsch; 1986 May; 43(5):365-71. PubMed ID: 2941889
    [No Abstract]   [Full Text] [Related]  

  • 23. Third generation oral contraceptive pills.
    MacRae K; Kay C
    BMJ; 1995 Oct; 311(7013):1112. PubMed ID: 7580698
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical evaluation of desogestrel, the first new-generation progestagen, practil 21, on 13,290 women and 74,967 cycles].
    Bilotta P; Favilli S
    Minerva Ginecol; 1987 Dec; 39(12):855-69. PubMed ID: 3329705
    [No Abstract]   [Full Text] [Related]  

  • 25. Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism.
    Lewis MA; Spitzer WO; Heinemann LA; MacRae KD; Bruppacher R
    BMJ; 1997 Sep; 315(7109):679-80. PubMed ID: 9310583
    [No Abstract]   [Full Text] [Related]  

  • 26. Department of health changes advice on third generation pills.
    Mayor S
    BMJ; 1999 Apr; 318(7190):1026. PubMed ID: 10205088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill.
    Black C; Kaye JA; Jick H
    Br J Clin Pharmacol; 2002 Jun; 53(6):637-40. PubMed ID: 12047488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
    Bilotta P; Favilli S
    Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Effects of desogestrel + ethinylestradiol on the haemostatic balance.
    Rákóczi I; Gerö G; Demeter J; Gáti I
    Arzneimittelforschung; 1985; 35(3):630-3. PubMed ID: 3158320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
    Akerlund M
    Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene.
    Serfaty D; Vree ML
    Eur J Contracept Reprod Health Care; 1998 Dec; 3(4):179-89. PubMed ID: 10036600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
    BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral contraception and venous thromboembolism. A New Zealand perspective.
    Roke C
    Drug Saf; 1997 Feb; 16(2):79-87. PubMed ID: 9067120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral contraceptives and venous thromboembolism.
    Speroff L
    Int J Gynaecol Obstet; 1996 Jul; 54(1):45-50. PubMed ID: 8842817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deep vein thrombophlebitis of a leg in a young female with heterozygous protein C deficiency taking oral contraceptives.
    Simioni P; Lazzaro AR; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(3):443-5. PubMed ID: 1703114
    [No Abstract]   [Full Text] [Related]  

  • 38. Oral contraceptives and venous thromboembolism.
    Lawrenson R; Farmer R
    N Z Med J; 1997 Feb; 110(1038):63. PubMed ID: 9076294
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk of idiopathic cerebral haemorrhage in women on oral contraceptives with differing progestagen components.
    Jick SS; Myers MW; Jick H
    Lancet; 1999 Jul; 354(9175):302-3. PubMed ID: 10440310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factor V Leiden and third-generation oral contraceptives.
    Westhoff C
    Lancet; 1996 Feb; 347(8998):396-7. PubMed ID: 8598719
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.